Characteristic | No screening (N = 94) | No follow-up (N = 22) | Test/screening failure (N = 35) | Total (N = 151) | p valueǂ |
---|---|---|---|---|---|
Median age at diagnosis [IQR] | 53 [44–62] | 46 [36–55] | 44 [34–58] | 51 [40–59] | 0.007** |
Median year of diagnosis | 2013 | 2014 | 2013 | 2013 | 0.898 ± |
[IQR] | [2011–2016] | [2011–2016] | [2010–2016] | [2011–2016] | |
Race/Ethnicity | |||||
White, non-Hispanic | 53 (56) | 14 (64) | 27 (77) | 94 (62) | 0.527 |
Black, non-Hispanic | 26 (28) | 6 (27) | 6 (17) | 38 (25) | |
Hispanic | 11 (12) | 2 (9) | 2 (6) | 15 (10) | |
Other | 4 (4) | 0 (0) | 0 (0) | 4 (3) | |
Symptoms at diagnosis | |||||
Yes | 81 (86) | 15 (69) | 21 (60) | 117 (78) | 0.004** |
No/unknown | 13 (14) | 7 (32) | 14 (40) | 34 (22) | |
Immunocompromised | |||||
Yes | 5 (5) | 1 (5) | 1 (3) | 7 (5) | 1.000 |
No/unknown | 89 (95) | 21 (95) | 29 (97) | 144 (95) | |
Current/Past smoker | |||||
Yes | 45 (48) | 16 (73) | 10 (29) | 71 (47) | 0.005** |
No/unknown | 49 (52) | 6 (27) | 25 (71) | 80 (53) | |
Histology type | |||||
Squamous | 61 (65) | 18 (82) | 15 (43) | 94 (62) | 0.019* |
Non-squamous | 31 (33) | 4 (18) | 20 (57) | 55 (36) | |
Unknown | 2 (2) | 0 (0) | 0 (0) | 2 (1) | |
Stage (FIGO) | |||||
Stage I-IIA (local) | 45 (48) | 16 (73) | 25 (71) | 86 (57) | 0.011* |
Stage IIB-IV (advanced) | 47 (50) | 5 (23) | 8 (23) | 60 (40) | |
Unknown/missing | 2 (2) | 1 (4) | 2 (6) | 5 (3) | |
History of underinsurancea | |||||
Yes | 36 (38) | 7 (32) | 4 (11) | 47 (31) | 0.014* |
No/unknown | 58 (62) | 15 (68) | 31 (89) | 104 (69) | |
Other barriersb | |||||
None | 60 (64) | 12 (55) | 26 (74) | 98 (65) | 0.296 |
1 or more barriers | 34 (36) | 10 (45) | 9 (26) | 53 (35) |